In Bid For Allergan Inc., Valeant Pharmaceuticals International Defends Its Record On Research

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

As it pursues a hostile takeover of Allergan, Valeant has reiterated time and again its belief that most pharmaceutical research and development doesn’t pay off.

Seeking to defend itself, Allergan has seized on those comments, accusing Valeant of being more concerned with financial engineering than with innovation. Formally rejecting Valeant’s latest offer on Tuesday with a news release and slide show, Allergan trumpeted its own research successes while pillorying Valeant’s approach.

Help employers find you! Check out all the jobs and post your resume.

Back to news